Identification and description of low testosterone among male patients treated with crizotinib
We will calculate the number of MALE patients currently treated with crizotinib, who have not yet had testosterone checked on drug and who are not currently on testosterone replacement therapy. We will perform the following:
1. For each patient for whom we check Testosterone (T), we will complete an initial assessment form documenting testosterone levels and the presence or absence of associated symptoms.
2. 2-4 months after the first testosterone assessment (regardless of the initial level and requirement for replacement), we will recheck the testosterone level and repeat symptom assessment.
Study Procedures: Case identification. Data collection forms will be completed and submitted to Dr. Ross Camidge (study PI) at the University of Colorado Cancer Center.
Male patients on crizotinib for at least 21 days.